Goldman Sachs analyst Chris Shibutani upgraded AbbVie to Buy from Neutral with a $173 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABBV:
- Genmab, AbbVie announce new data from Phase 1/2 EPCORE NHL-1 trial
- After AbbVie agrees to buy Cerevel, analysts weigh in on who may be next
- Cerevel Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
- M & A News: AbbVie (NYSE:ABBV) Doubles Down on Acquisitions, Buys CERE for $8.7B
- AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
Questions or Comments about the article? Write to editor@tipranks.com